Last reviewed · How we verify
donor-derived CIK cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
donor-derived CIK cells (donor-derived CIK cells) — A.O. Ospedale Papa Giovanni XXIII.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| donor-derived CIK cells TARGET | donor-derived CIK cells | A.O. Ospedale Papa Giovanni XXIII | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- donor-derived CIK cells CI watch — RSS
- donor-derived CIK cells CI watch — Atom
- donor-derived CIK cells CI watch — JSON
- donor-derived CIK cells alone — RSS
Cite this brief
Drug Landscape (2026). donor-derived CIK cells — Competitive Intelligence Brief. https://druglandscape.com/ci/donor-derived-cik-cells. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing